Related Experiment Videos
p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours
C Guillot1, N Falette, M P Paperin
1INSERM U453, Centre Léon Bérard, Lyon, France.
Abstract:
Functional inactivation of the wild-type p53 protein has been described in different human cancers. Since a significant proportion of breast tumours express wild-type TP53, the p53 antiproliferative activity could be inactivated in transformed mammary epithelial cells by a mechanism independent on structural alteration of the gene. To test this hypothesis, we analysed the p53 activity in primary breast tumour cells. As a preliminary study, we demonstrated in breast adenocarcinoma cell lines that the nuclear accumulation of the inhibitor of cyclin dependent kinase p21(WAFl/CIP1), in response to adriamycin treatment, specifically reflected the activity of a functional wild-type p53 protein. Then, we used this strategy to study the p53 activity in 23 primary breast tumours. p21(WAF1/CIP1 accumulation was detected in all tumours expressing wild-type TP53. In contrast, no p21(WAF1/CIP1) response was detected in cells harboring a mutant TP53 gene. This report is the first functional study of p53 in primary breast tumours. The results demonstrate that TP53 mutation represents the only common mechanism leading to an irreversible inactivation of p53 functions in this cancer type.
Insights
Wild-type p53 protein inactivation in breast tumors was studied. Functional analysis revealed that TP53 gene mutation is the sole common mechanism for irreversible p53 inactivation in breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Wild-type p53 protein inactivation occurs in various human cancers.
- A significant proportion of breast tumors express wild-type TP53, suggesting potential p53 inactivation mechanisms independent of gene mutation.
- Understanding p53 functional status in breast cancer is crucial for therapeutic strategies.
Purpose of the Study:
- To investigate the functional activity of wild-type p53 protein in primary breast tumor cells.
- To determine if TP53 gene mutation is the primary mechanism for p53 inactivation in breast cancer.
Main Methods:
- Utilized breast adenocarcinoma cell lines to establish a functional assay.
- Assessed p53 activity by measuring nuclear accumulation of p21(WAF1/CIP1) in response to adriamycin treatment.
- Applied this functional assay to analyze p53 activity in 23 primary breast tumors.
Main Results:
- Adriamycin-induced nuclear accumulation of p21(WAF1/CIP1) served as a reliable indicator of functional wild-type p53.
- p21(WAF1/CIP1) accumulation was observed in all tumors with wild-type TP53.
- No p21(WAF1/CIP1) response was detected in breast tumors harboring a mutant TP53 gene.
Conclusions:
- TP53 mutation is the predominant and common mechanism leading to irreversible inactivation of p53 functions in breast cancer.
- This study provides the first functional analysis of p53 in primary breast tumors.
- The findings underscore the importance of TP53 mutation status in understanding breast cancer biology.